|
Back to EZorb Newsletter Index |
|
In this issue:
1. Share Success: Letters From Readers Letter I: From Donna Hi, my name is Donna. I have been taking ezorb for about 7 months now. I have noticed a remarkable difference. I refused all drugs, and am glad I did. I have osteo and am going thru the change of life. I also have noticed the growth of my fingernails. This product sure works for the colon as well. My husband is also taking ezorb and loves it too. I am so glad I came across this product. A good way for people out there to get exercise is on a rebounder. It is fun and a wonderful way to exercise. The cost is quite cheap. Thanks again ezorb. I can hardly wait for my next bone density check. Donna Letter II:
From John This is John from Iowa. I found Ezorb on the internet about 3 years ago. My wife and I had been taking lots of algae calcium. I started getting a heel spur which I shouldn't have had if I had been getting enough calcium. I typed in “heel spur” on the computer and found Ezorb. It made sense to me and I ordered some. In 3 weeks my heel spur was gone. Our whole family is using Ezorb. My wife should have a bone density test again as she had osteoporosis real bad. I had had the bone test on my heel and I wasn't real good either. We tried a plant based calcium for a while but went back to Ezorb. That is where we will stay. Keep up the good work. From the Desk of EZorb Newsletter Editor:Our newsletter reaches over 230,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life. Please email your story to sharesuccess@ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Reflux Severity Indicates Interstitial Lung Disease ProgressionPost-hoc analysis of a randomised trial shows that the severity of reflux symptoms in patients with systemic sclerosis (SSc) predicts radiographic progression of interstitial lung disease (ILD). As reported in Arthritis Care & Research, Elizabeth Volkmann (University of California, Los Angeles, USA) and co-researchers explored the association using data from the Scleroderma Lung Study II randomised trial. They explain that while a cross-sectional relationship is well established, the dataset from this trial “provided a unique opportunity to examine how the severity of esophageal reflux at baseline is related to radiographic ILD progression over time”. The baseline average reflux scale score, available for 141 of the 142 trial participants, was 0.57, indicating moderate reflux. Baseline quantitative interstitial lung disease (QILD) as a percentage of the whole lung was about 30% and quantitative lung fibrosis (QLF) about 8.5%. During the 24 months of trial follow-up, the baseline reflux score was positively associated with changes in QLF, both for the whole lung and the lobe of maximal involvement, such that patients with more severe reflux either had less improvement or progressed relative to those with less reflux. This association persisted after accounting for variables including trial medication, baseline QLF score and proton-pump inhibitor use. Baseline reflux score was also independently associated with changes in QILD, albeit only for the whole lung. Of note, the researchers found that oesophageal diameter and area were not significantly associated with either baseline reflux severity or ILD progression, despite these having been proposed as independent and objective measures of oesophageal involvement in SSc. Reflux severity was not, on the whole, associated with baseline measures of ILD; however, Volkmann and team highlight a “weak correlation” between reflux severity and ground glass opacity in the lobe of maximum involvement. They say this could indicate that aspiration resulting from oesophageal reflux could “perpetuate pulmonary inflammation and fibrosis in SSc”, but caution that further prospective research is needed to determine this. More research is also required “to determine whether other treatments aimed at reducing aspiration events due to gastro-oesophageal reflux disease (e.g., promotility agents), could improve outcomes for patients with SSc-ILD”, say the study authors. They conclude: “Optimizing the treatment of esophageal involvement in SSc not only may provide symptomatic relief for patients, but it may also represent a life-extending measure for patients with this often-fatal disease.” Original research was published in Arthritis Care Res 2022; doi:10.1002/acr.25070. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix. |
|
Back to EZorb Newsletter Index |